Anthracycline-Induced Hepatitis B Reactivation in Solid Organ Cancers: A Multicenter Study

Basit Öğe Kaydı
dc.authoridKoral, Lokman / 0000-0003-4646-4591
dc.contributor.authorUgraklı, Muzaffer
dc.contributor.authorAraz, Murat
dc.contributor.authorKoçak, Mehmet Zahid
dc.contributor.authorUgraklı, Selin
dc.contributor.authorEr, Muhammed Muhiddin
dc.contributor.authorHendem, Engin
dc.contributor.authorGürbüz, Ali Fuat
dc.date.accessioned2025-05-29T02:57:37Z
dc.date.available2025-05-29T02:57:37Z
dc.date.issued2024
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractObjectives: Hepatitis B reactivation is extremely rare in HBsAg-negative/Anti-HBcIgG-positive patients receiving chemotherapy for solid organ cancer in our current practice. In our study, we aimed to investigate the frequency of reactivation and associated risk factors in patients with solid tumors receiving anthracycline-based chemotherapy. Methods: In the study, the records of 3147 patients with solid tumors receiving anthracycline chemotherapy were examined retrospectively. HBsAg negative/Anti-HBcIgG positivity was detected in 196 (6.2%) of the patients. Results: Elevated liver enzymes were found in 45 patients, with the identified causes being adverse effects of chemotherapeutics in 18 (9.1%), liver metastasis in 11 (5.5%), use of antibiotics and analgesics in 7 (3.6%), herbal medications in 7 (3.6%), and Hepatitis B reactivation in 2 (1%) patients. Patients who developed Hepatitis B reactivation had Rheumatoid Arthritis and Systemic Lupus Erythematosus, and were on steroids. Conclusion: In our study, the rates of hepatitis B reactivation after anthracycline chemotherapy in HBsAg negative/ Anti-HBcIgG positive solid tumor patients were found to be lower than those reported in the literature. Our results suggest that prophylactic strategies for hepatitis B reactivation should be repeatedly considered in this group of patients.
dc.identifier.doi10.14744/ejmo.2024.38797
dc.identifier.endpage423
dc.identifier.issn2587-196X
dc.identifier.issue4
dc.identifier.startpage417
dc.identifier.urihttps://doi.org/10.14744/ejmo.2024.38797
dc.identifier.urihttps://hdl.handle.net/20.500.12428/30104
dc.identifier.volume8
dc.identifier.wosWOS:001455559400005
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherAccscience Publishing
dc.relation.ispartofEurasian Journal of Medicine and Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250529
dc.subjectAntiviral prophylaxis
dc.subjecthepatitis b virus
dc.subjecthepatic reactivation
dc.subjectsolid malignancies
dc.titleAnthracycline-Induced Hepatitis B Reactivation in Solid Organ Cancers: A Multicenter Study
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Lokman Koral_Makale.pdf
Boyut:
177.62 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu